FOLH1 and cancer: We addressed this void and relied on the FRAMCAP database (Frankfurt Metastatic Cancer Database of the Prostate) to compare cancer-control outcomes such as PFS and overall survival in Lu-PSMA treated taxan-naïve mCRPC patients vs. the current standard of care.